olaparib (Lynparza)

following a full submission assessed under the end of life and orphan equivalent medicine process:

olaparib (Lynparza®) is accepted for use within NHSScotland.

Indication under review: as monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.

In a phase III study in men with metastatic castration-resistant prostate cancer who had disease progression while receiving a new hormonal agent and had a BRCA1, BRCA2 or ATM mutation, olaparib was superior to treatment with a new hormonal agent measured by progression free survival.

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower. This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.